1 / 1

Effectiveness of Rituximab treatment in primary Sjögren’s syndrome

Effectiveness of Rituximab treatment in primary Sjögren’s syndrome A randomized, double-blind, placebo-controlled trial JM Meijer, et al. Arthritis Rheum 2010. Rituximab, AC monoclonal anti-CD20 (LMNH, PR, lupus…) SSP, BGSA+, FR et anti-SSA/SSB, majeur, débit salivaire  0,15 ml/min

kirby
Télécharger la présentation

Effectiveness of Rituximab treatment in primary Sjögren’s syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effectiveness of Rituximab treatment in primary Sjögren’s syndrome A randomized, double-blind, placebo-controlled trial JM Meijer, et al. Arthritis Rheum 2010 • Rituximab, AC monoclonal anti-CD20 (LMNH, PR, lupus…) • SSP, BGSA+, FR et anti-SSA/SSB, majeur, débit salivaire  0,15 ml/min • Rituximab 1000 mg J1J15 (n=20) vs placebo (n=10) Effet sur débit salivaire, fatique, scores de sd sec, signes extra-gland. Bonne tolérance (1 cas de maladie sérique) Dans le SSP, le Rituximab améliore le débit salivaire chez les patients ayant un débit résiduel, avec un bon ratio bénéfice/risque

More Related